Skip to content

The Anxiolytic

Selank

Summary coverage

At a glance

What it is
An anxiolytic peptide studied for stress-related sleep disruption.
Evidence
Practitioner experience onlyHow the tiers workOur material lists Selank in a single comparison table with a described mechanism and use case but cites no study, no dose and no timeline for it. Why this tier
Half-life
Not established in available literature
Routes
Not established in available literature
Category
Cognitive, Sleep
FDA
Nomination withdrawn
As of 3 August 2026. What that means
WADA
We do not state a status

Not schedulable in Claritide. Our sources publish no dosing figure for Selank, so there is nothing to build a schedule from.

Evidence

Why this tier

Our material lists Selank in a single comparison table with a described mechanism and use case but cites no study, no dose and no timeline for it.

Overview

What it is

Selank appears in our material as a sleep-adjacent peptide working through GABA modulation and anxiolytic effects, targeted at anxiety-driven insomnia rather than sleep architecture. Our sources publish no dosing figures, timeline or side effect profile for it.

Mechanism

How it works

Our material describes Selank as working through GABA modulation with an anxiolytic effect. GABA is the brain's primary calming neurotransmitter; compounds that modulate it reduce the nervous system arousal that keeps people awake. That places Selank in a different position from DSIP, which acts on sleep depth, and from the GHRPs, which act through growth hormone. Selank targets the anxiety that prevents sleep rather than the sleep itself. Our sources do not describe the receptor-level mechanism further.

Dosing

Commonly researched ranges

These are figures reported in published literature and practitioner protocols: a commonly researched range, not a recommendation. Claritide does not tell you what to take.

Not established in available literature. Our sources describe Selank without publishing a dosing figure, so Claritide does not print one.

Cycle guidance
Not established in available literature
Goals
Sleep, Cognition
Legal standing

Where this sits with the FDA

Dated, sourced, and separate from whether it works. Removal from a warning list is not permission to compound.
Nomination withdrawnas of 3 August 2026 · US

FDA 503A bulks · nomination withdrawn

Off the nomination list and not on the 503A bulks list: limbo, not permission. Selank is registered in Russia as a medicine, nasal drops for anxiety sold without a prescription.

Last change · Nomination withdrawn in the September 2024 tranche; the exact date is not verified in our sources.

Primary source
Sport

WADA status

The 2026 Prohibited List entered force on 1 January 2026.
We do not state a status

Not named on WADA’s 2026 Prohibited List. Its S0 section also bans drugs it does not name, when no government health authority currently approves them for human treatment. Selank is registered in Russia as a medicine, nasal drops for anxiety sold without a prescription. So S0 may not cover it, and we do not state a status.

We looked and could not resolve it. This is not the same as "not prohibited". Treat it as unresolved and check with your federation before competing.

Reconstitution

Mixing recipes our sources document

Concentration (mg/mL) = vial mg ÷ diluent mL. On a U-100 barrel, 1 unit = 0.01 mL.

Not established in available literature. Use the calculator with the figures printed on your own vial.
Open the calculator

Expectations

Week by week

What our material describes people reporting. Individual responses vary widely.

Not established in available literature.

Tolerability

Side effects

Grouped by how often our sources report them. Percentages appear only where a published trial figure exists.

Not established in available literature. Absence from this page does not mean absence of risk. It means our sources publish no side-effect profile for Selank.

Safety

Contraindications and interactions

Do not use if

  • Our sources do not publish a contraindication list for Selank beyond general research-peptide caution

Interactions

  • CNS-active medicationscaution

    The Playbook advises against combining any peptide with CNS-active medication without physician awareness; Selank is described as acting on GABA.

Absence from this list does NOT mean safety. It means lack of research.

Handling

Storage and cost

Storage
Our sources do not publish storage guidance specific to Selank. General peptide storage rules apply to any lyophilized research peptide.
Cost
Not established in available literature
Combinations

Stacks with

Only pairings our own material actually documents. Stacking is the least evidence-based part of this field.
Deep dive

Selank in full

Limited coverage

Selank appears once in our material, in the "other peptides for sleep" table on our DSIP page. One row. We cite no study, no dose, no cycle length, no timeline and no side effect profile.

What our sources do say

The table gives three fields. Primary sleep effect: anxiety-driven insomnia. Mechanism: GABA modulation, anxiolytic. Best for: stress-related sleep issues.

That places it in a distinct position among the sleep compounds we cover. DSIP acts on sleep depth, delta-wave architecture. Epitalon acts on sleep timing, circadian rhythm through pineal melatonin. The GHRPs act indirectly through growth hormone pulses during slow-wave sleep. Selank, as our material describes it, acts on the anxiety that prevents sleep in the first place.

The GABA overlap worth noting

DSIP also touches the GABA system, and DSIP's contraindication list includes benzodiazepines, other CNS depressants and ACE inhibitors specifically because of that overlap. The Playbook's broader rule is that no peptide should be combined with CNS-active medication without physician awareness.

Selank is described as acting on the same system. We flag that as a caution rather than a documented interaction, because it is inference from mechanism rather than a finding in our sources, and the distinction between those two things is the whole point of an evidence tier.

What this record cannot tell you

How much, how often, when, for how long, or what to expect. Our library does not hold those answers for Selank. Absence from our data is absence of research in our sources, not a safety signal in either direction.

References

Sources

  1. 1
    Eurasian Economic Union · unified register of medicines: Selank® 0.15% nasal drops, LP-(010951)-(RG-RU), 15 July 2025, registered in Russia, non-prescription (read 28 September 2026)

Every record in this library is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.